A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2017 Results (n=6) from phase I portion of the study assessing safety of pembrolizumab with gemcitabine in patients with previously treated advanced non-small cell lung cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 23 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top